Clinical Trials
1,290 trialsSTARTRK-2
Hoffmann-La Roche
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
National Cancer Institute (NCI)
AndroMETa-CRC
AbbVie
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
FORBES
Sun Yat-sen University
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
NEST-1
Weill Medical College of Cornell University
PICC-3
Sun Yat-sen University
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Medical
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Fudan University
RILUZOX-01
UNICANCER
PARERE
Gruppo Oncologico del Nord-Ovest
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
COLIBRI-GI
UNICANCER
CLOVER
CytoDyn, Inc.
VISTA-1
Riboscience, LLC.
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
National Cancer Institute (NCI)
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
BioNTech SE
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
N01-A-PICIT-GI
Peking University People's Hospital
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
FALCO
Zhejiang University
CANTOR
AstraZeneca
Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy
Endevica Bio
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
panSOHO
Bayer
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Sun Yat-sen University
COMPANION-003
Compass Therapeutics
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Cedars-Sinai Medical Center
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Virginia Commonwealth University
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
Tianjin Medical University Cancer Institute and Hospital
JS212 Combination Therapies in Metastatic Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.
LEAP-005
Merck Sharp & Dohme LLC
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
CLEAR-04
Fudan University
CLEAR-03
Fudan University
CLEAR-01
Fudan University
CLEAR-02
Fudan University